Narrative Review: BRAF Opens the Door for Therapeutic Advances in MelanomaFLAHERTY, Keith T.Annals of internal medicine. 2010, Vol 153, Num 9, pp 587-591, issn 0003-4819, 5 p.Article

BRAF, a Target in Melanoma: Implications for Solid Tumor Drug DevelopmentFLAHERTY, Keith T; MCARTHUR, Grant.Cancer. 2010, Vol 116, Num 21, pp 4902-4913, issn 0008-543X, 12 p.Article

BRAF in Melanoma: Current Strategies and Future DirectionsSALAMA, April K. S; FLAHERTY, Keith T.Clinical cancer research (Print). 2013, Vol 19, Num 16, pp 4326-4334, issn 1078-0432, 9 p.Article

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance : Drug Development: What Experience Has Taught UsMARZUKA ALCALA, Alexander; FLAHERTY, Keith T.Clinical cancer research (Print). 2012, Vol 18, Num 1, pp 33-39, issn 1078-0432, 7 p.Article

Sorafenib and sunitinib in renal cell carcinomaSTEIN, Mark N; FLAHERTY, Keith T.Clinical cancer research. 2007, Vol 13, Num 13, pp 3765-3770, issn 1078-0432, 6 p.Article

Resistance to BRAF-targeted therapy in melanomaSULLIVAN, Ryan J; FLAHERTY, Keith T.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1297-1304, issn 0959-8049, 8 p.Article

New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic AdvancesFLAHERTY, Keith T; FISHER, David E.Clinical cancer research (Print). 2011, Vol 17, Num 15, pp 4922-4928, issn 1078-0432, 7 p.Article

Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted TherapySMALLEY, Keiran S. M; NATHANSON, Katherine L; FLAHERTY, Keith T et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 8, pp 3241-3244, issn 0008-5472, 4 p.Article

The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will BeSULLIVAN, Ryan J; LORUSSO, Patricia M; FLAHERTY, Keith T et al.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5283-5291, issn 1078-0432, 9 p.Article

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaFLAHERTY, Keith T; PUZANOV, Igor.Biochemical pharmacology. 2010, Vol 80, Num 5, pp 638-646, issn 0006-2952, 9 p.Article

Melanoma: New Insights and New TherapiesNIKOLAOU, Vasiliki A; STRATIGOS, Alexander J; FLAHERTY, Keith T et al.Journal of investigative dermatology. 2012, Vol 132, Num 3, pp 854-863, issn 0022-202X, 10 p., 2Article

p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK InhibitionZHENYU JI; NI NJAUW, Ching; TAYLOR, Michael et al.Journal of investigative dermatology. 2012, Vol 132, Num 2, pp 356-364, issn 0022-202X, 9 p.Article

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancyFLAHERTY, Keith T; STEVENSON, James P; HAHN, Stephen M et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 3, pp 217-222, issn 0344-5704, 6 p.Article

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaTRUNZER, Kerstin; PAVLICK, Anna C; HERSEY, Peter et al.Journal of clinical oncology. 2013, Vol 31, Num 14, pp 1767-1774, issn 0732-183X, 8 p.Article

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsFLAHERTY, Keith T; INFANTE, Jeffery R; KUDCHADKAR, Ragini et al.The New England journal of medicine. 2012, Vol 367, Num 18, pp 1694-1703, issn 0028-4793, 10 p.Article

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohortLU SI; YAN KONG; XIAOWEI XU et al.European journal of cancer (1990). 2012, Vol 48, Num 1, pp 94-100, issn 0959-8049, 7 p.Article

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysMEHNERT, Janice M; MCCARTHY, Mary M; JILAVEANU, Lucia et al.Human pathology. 2010, Vol 41, Num 3, pp 375-384, issn 0046-8177, 10 p.Article

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignanciesBILENKER, Joshua H; STEVENSON, James P; FLAHERTY, Keith T et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 4, pp 357-360, issn 0344-5704, 4 p.Article

Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF InhibitorsACKERMAN, Allison; KLEIN, Oliver; MENZIES, Alexander M et al.Cancer. 2014, Vol 120, Num 11, pp 1695-1701, issn 0008-543X, 7 p.Article

Phase 1 and Pharmacodynamic Trial of Everolimus in Combination With Cetuximab in Patients With Advanced CancerCIUNCI, Christine A; PERINI, Rodolfo F; DIVGI, Chaitanya R et al.Cancer. 2014, Vol 120, Num 1, pp 77-85, issn 0008-543X, 9 p.Article

Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma: A Retrospective Review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne ExperienceLUKE, Jason J; CALLAHAN, Margaret K; FLAHERTY, Keith T et al.Cancer. 2013, Vol 119, Num 20, pp 3687-3695, issn 0008-543X, 9 p.Article

Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaFLAHERTY, Keith T; ROBERT, Caroline; DUMMER, Reinhard et al.The New England journal of medicine. 2012, Vol 367, Num 2, pp 107-114, issn 0028-4793, 8 p.Article

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)POULIKAKOS, Poulikos I; PERSAUD, Yogindra; SALTON, Maayan et al.Nature (London). 2011, Vol 480, Num 7377, pp 387-390, issn 0028-0836, 4 p.Article

Drug Targeting of Oncogenic Pathways in MelanomaFECHER, Leslie A; AMARAVADI, Ravi K; SCHUCHTER, Lynn M et al.Hematology/oncology clinics of North America. 2009, Vol 23, Num 3, issn 0889-8588, x, 599-618 [20 p.]Article

Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiationPLASTARAS, John P; KIM, Seok-Hyun; DIEHL, J. Alan et al.Cancer research (Baltimore). 2007, Vol 67, Num 19, pp 9443-9454, issn 0008-5472, 12 p.Article